You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in...
Keep Reading →
July 3 - News
After gaining Food and Drug Administration approval nearly a year ago, patients can finally walk into a pharmacy and get their prescription for VIVUS, Inc.
Keep Reading →
July 3 - News
While the analysis of peak sales and potential patient populations may be appealing to most, it costs a great deal of money to launch a new product with success.
Keep Reading →
July 1 - News
The news flow from biotech companies might slow down during the summer, but it won't stop.
Keep Reading →
July 1 - News
If that word is "disease," it could be billions of dollars. The American Medical Association, or AMA, recently decided to categorize obesity as a disease.
Keep Reading →
July 1 - News
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
Keep Reading →
June 27 - News
Cheap generic versions of Pfizer Inc. (NYSE:PFE)'s Viagra are coming to Europe, according the generic-drug maker Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
June 27 - News
After almost a decade, the FDA has once again started approving obesity drugs. VIVUS, Inc. (NASDAQ:VVUS)’s Qysmia and Arena Pharmaceuticals, Inc.
Keep Reading →
June 27 - News
Editor's Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc.
Keep Reading →
June 27 - News
Proxy fights are like the demolition derby of the investment world.
Keep Reading →
June 27 - News
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Keep Reading →
June 27 - News
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
Keep Reading →
June 27 - News
First investors were reminded of the struggle between VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc.
Keep Reading →
June 27 - News
A historic view of recurring themes in major wartime conflicts, our puzzling tendency to continuously overeat, and the pie-in-the-sky popularity of Charles Duhigg's The Power ...
Keep Reading →
June 27 - News
In the financial blogosphere, there are lots of tools for VIVUS, Inc. (NASDAQ:VVUS) readers to track, but it's smart to be aware of a stock's short interest.
Keep Reading →
June 25 - News
The easiest route would involve the companies with the biggest share price movements.
Keep Reading →
June 25 - News
After years of anticipation by doctors, patients, and investors, Belviq was finally launched last week for treatment of obesity, type 2 diabetes and overweight patients with a...
Keep Reading →
June 20 - News
Editor's Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Orexigen Therapeutics, Inc.
Keep Reading →
June 20 - News
The decision wasn't without debate, though. In fact, the AMA's Council on Science and Public Health actually recommended against calling obesity a disease.
Keep Reading →
June 19 - News
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
Keep Reading →
June 19 - News
The U.S. weight loss market is estimated at $61 billion, with the global weight management market expected to be $650 billion by 2015.
Keep Reading →
June 18 - News
In the "Global Burden of Disease" report from the World Health Organization, which was compiled over a 20-year period from 1990 through 2010 using data from 500 researchers from...
Keep Reading →
June 17 - News
According to most stock holders, hedge funds are viewed as underperforming, old financial vehicles of the past.
Keep Reading →
June 14 - News
Arena Pharmaceuticals, Inc.
Keep Reading →
June 10 - News
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)' Belviq, the newest offering, looks relatively safe.
Keep Reading →
June 10 - News
Often referred to as "the silent killer," stroke is the fourth-leading cause of the death in the U.S., behind only heart disease, cancer, and chronic lower respiratory diseases...
Keep Reading →
June 10 - News
Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS, Inc. (NASDAQ:VVUS) .
Keep Reading →
June 6 - Hedge Funds
When we think of big pharma companies, the company we think about constantly is Pfizer Inc.
Keep Reading →
June 6 - News
Editor's Note: Related tickers: Infosys Ltd ADR (NYSE:INFY), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Marathon Petroleum Corp (NYSE:MPC), VIVUS, Inc.
Keep Reading →
June 5 - Hedge Funds
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
Keep Reading →
June 3 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds' portfolio at the end of March.
Keep Reading →
June 3 - News
Is VIVUS, Inc. (NASDAQ:VVUS) a good investment today? Money managers are in a pessimistic mood.
Keep Reading →
June 2 - News
The U.S., which ranks as the most obese nation in the world according to the Organization for Economic Cooperation and Development, has seen a relatively steady increase over ...
Keep Reading →
May 31 - News
As recently as a decade ago, the biggest hurdle for biotech companies wasn't competition from their peers or even the sale price of their drugs.
Keep Reading →
May 29 - News
VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc.
Keep Reading →
May 28 - News
When investors are looking to fill out their retirement portfolios, they would be wise to give a long, hard look at Johnson & Johnson (NYSE:JNJ) stock.
Keep Reading →
May 28 - News
With the Organisation for Economic Co-operation and Development pinpointing the United States as the most obese country in the world, it can be hard to find many positives with...
Keep Reading →
May 28 - News
A whopping 25.3 million people in the U.S. right now are diabetic, with an additional 79 million Americans in the pre-diabetes stage.
Keep Reading →
May 28 - News
Editor's Note: The original article incorrectly stated Schedule IV drugs are the second-most-restrictive.
Keep Reading →
May 24 - News
Are macro funds finally staging a comeback this year? After posting disappointing numbers in 2012 -- when the average macro-focused hedge fund fell by 0.40 percent, according ...
Keep Reading →
May 24 - Hedge Funds
The obesity drug space is becoming increasingly complex and hard to predict. After months of waiting patiently, Arena Pharmaceuticals, Inc.
Keep Reading →
May 23 - News
Obesity is a growing pandemic for many industrialized nations, especially in the U.S., where it now affects almost 36% of adults and 17% of adolescents.
Keep Reading →
May 23 - News
The study tracked men with ADHD for more than 30 years and found that a whopping 41% of them were obese compared to 22% of patients in a matched control group who didn't have ...
Keep Reading →
May 22 - News
The rate of worldwide obesity has been marching higher at an extraordinary rate for more than three decades now.
Keep Reading →
May 20 - News
The Food and Drug Administration approved the weight-loss therapy Belviq from Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in June 2012.
Keep Reading →
May 18 - News
It wasn't that long ago that obesity drugs were considered a lifestyle drug. Doctors, the Food and Drug Administration, and insurers believed losing weight was a vanity issue.
Keep Reading →
May 16 - News
Things are beginning to look slightly up for obesity drugmaker VIVUS, Inc. (NASDAQ:VVUS) -- mere weeks before a competing drug from Arena Pharmaceuticals, Inc.
Keep Reading →
May 14 - News
Short interest in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is 28.81% of its float.
Keep Reading →
May 13 - News
